62 related articles for article (PubMed ID: 38706605)
1. Prognostic analysis of patients with combined hepatocellular-cholangiocarcinoma after radical resection: A retrospective multicenter cohort study.
Zhang G; Chen BW; Yang XB; Wang HY; Yang X; Xie FC; Chen XQ; Yu LX; Shi J; Lu YY; Zhao HT
World J Gastroenterol; 2022 Nov; 28(41):5968-5981. PubMed ID: 36405111
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of myosteatosis in patients with lung cancer: a systematic review and meta-analysis.
Feng S; Mu H; Hou R; Liu Y; Zou J; Zhao Z; Zhu Y
Int J Clin Oncol; 2022 Jul; 27(7):1127-1138. PubMed ID: 35604501
[TBL] [Abstract][Full Text] [Related]
3. The coexistence of myosteatosis and the creatinine/cystatin C ratio are determinants of outcomes in cholangiocarcinoma patients undergoing curative surgery.
Liu Y; Zhang J; Song G; Ding X; Sun H; Zhou J; Jing X
Front Oncol; 2024; 14():1233768. PubMed ID: 38706605
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Myosteatosis and Creatinine-to-Cystatin C Ratio in Patients with Pancreatic Cancer Who Underwent Radical Surgery.
Bi S; Jiang Y; Guan G; Sun X; Wang X; Zhang L; Jing X
Ann Surg Oncol; 2024 May; 31(5):2913-2924. PubMed ID: 38319516
[TBL] [Abstract][Full Text] [Related]
5. Sarcopenia and myosteatosis diagnostic tool for gastrointestinal cancer: creatinine to cystatin C ratio as evaluation marker.
Liu H; Wang J; Tan S; Zhang Z; Yan M; Han J; Sui X; Yang F; Wu G
J Transl Med; 2023 Oct; 21(1):744. PubMed ID: 37864250
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of sarcopenia combined with preoperative fibrinogen-albumin ratio in patients with intrahepatic cholangiocarcinoma after surgery: A multicenter, prospective study.
Yu H; Wang M; Wang Y; Yang J; Deng L; Bao W; He B; Lin Z; Chen Z; Chen K; Zhang B; Liu F; Yu Z; Ye L; Jin B; Chen G
Cancer Med; 2021 Jul; 10(14):4768-4780. PubMed ID: 34105304
[TBL] [Abstract][Full Text] [Related]
7. Sarcopenia and Myosteatosis as Prognostic Markers in Patients with Advanced Cholangiocarcinoma Undergoing Palliative Treatment.
Jördens MS; Wittig L; Heinrichs L; Keitel V; Schulze-Hagen M; Antoch G; Knoefel WT; Fluegen G; Luedde T; Loberg C; Roderburg C; Loosen SH
J Clin Med; 2021 Sep; 10(19):. PubMed ID: 34640358
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications and predictive value of the creatinine‑cystatin C ratio in patients with multiple myeloma and renal impairment.
Sun Y; Zhao J; Du J; Li Y; Ding F; Zhao W
Oncol Lett; 2024 Mar; 27(3):134. PubMed ID: 38362231
[TBL] [Abstract][Full Text] [Related]
9. Extrahepatic Distal Cholangiocarcinoma vs. Pancreatic Ductal Adenocarcinoma: Histology and Molecular Profiling for Differential Diagnosis and Treatment.
Gkountakos A; Martelli FM; Silvestris N; Bevere M; De Bellis M; Alaimo L; Sapuppo E; Masetto F; Mombello A; Simbolo M; Bariani E; Milella M; Fassan M; Scarpa A; Luchini C
Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900245
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of 18 F-FDG PET/computed tomography metabolic parameters in predicting sarcopenia and prognosis of treatment-naive patients with non-small cell lung cancer.
Li D; Tan X; Yuan H; Yao X; Sun X; He L; Jiang L
Nucl Med Commun; 2023 Apr; 44(4):309-317. PubMed ID: 36756769
[TBL] [Abstract][Full Text] [Related]
11. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance.
Calvisi DF; Boulter L; Vaquero J; Saborowski A; Fabris L; Rodrigues PM; Coulouarn C; Castro RE; Segatto O; Raggi C; van der Laan LJW; Carpino G; Goeppert B; Roessler S; Kendall TJ; Evert M; Gonzalez-Sanchez E; Valle JW; Vogel A; Bridgewater J; Borad MJ; Gores GJ; Roberts LR; Marin JJG; Andersen JB; Alvaro D; Forner A; Banales JM; Cardinale V; Macias RIR; Vicent S; Chen X; Braconi C; Verstegen MMA; Fouassier L;
Nat Rev Gastroenterol Hepatol; 2023 Jul; 20(7):462-480. PubMed ID: 36755084
[TBL] [Abstract][Full Text] [Related]
12. Advanced endoscopy meets molecular diagnosis of cholangiocarcinoma.
Cadamuro M; Al-Taee A; Gonda TA
J Hepatol; 2023 May; 78(5):1063-1072. PubMed ID: 36740048
[TBL] [Abstract][Full Text] [Related]
13. Cystatin C proteoforms in chronic kidney disease.
Dahl H; Meyer K; Sandnes K; Welland NL; Arnesen I; Marti HP; Dierkes J; Lysne V
PLoS One; 2023; 18(2):e0269436. PubMed ID: 36724153
[TBL] [Abstract][Full Text] [Related]
14. Immunology and immunotherapy of cholangiocarcinoma.
Greten TF; Schwabe R; Bardeesy N; Ma L; Goyal L; Kelley RK; Wang XW
Nat Rev Gastroenterol Hepatol; 2023 Jun; 20(6):349-365. PubMed ID: 36697706
[TBL] [Abstract][Full Text] [Related]
15. Sarcopenia Predicts Prognosis of Patients Undergoing Liver Resection for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Zhang H; Zhang L; Wang Y; Zou J; Zhang T
Nutr Cancer; 2023; 75(3):776-784. PubMed ID: 36537813
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
